The pharmaceutical sector in 2017

The pharmaceutical industry will continue growing in 2017, despite the issues and the uncertainty caused by the new Trump Administration and by emerging markets slowing down. This is the view of Thilo Kaltenbach, pharmaceutical expert at consultancy Roland Berge. The acquisition fever will not subside in 2017, as shown by the interest in German Stada and the recent acquisition of Actelion by Johnson & Johnson for $30bn. The consolidation will be quite strong in the generics industry, in which an economy of scale will be increasingly supported, so as to reduce production cost. The Roland Berge’s analyst sees a trend for the next three years in the digitalization of pharma, which will allow outsiders such as Apple and Google to join the industry.
(Source Frankfurter Allgemeine Zeitung)